Related references
Note: Only part of the references are listed.Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease
Brian C. Shook et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade
Lyndsey E. Collins et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Antiparkinsonian Effects of Novel Adenosine A(2A) Receptor Antagonists
Anna Drabczynska et al.
ARCHIV DER PHARMAZIE (2011)
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Susan Duty et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
In Vivo Characterization of a Dual Adenosine A2A/A1 Receptor Antagonist in Animal Models of Parkinson's Disease
Brian C. Shook et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2010)
Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice
Daniel Marcellino et al.
NEUROBIOLOGY OF DISEASE (2010)
A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug
Annalisa Pinna et al.
NEUROPHARMACOLOGY (2010)
Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX
Lyndsey E. Collins et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2010)
Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines
Roger J. Gillespie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression
Robert A. Hodgson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
EFFECTS OF THE ADENOSINE A2A ANTAGONIST KW 6002 (ISTRADEFYLLINE) ON PIMOZIDE-INDUCED ORAL TREMOR AND STRIATAL c-Fos EXPRESSION: COMPARISONS WITH THE MUSCARINIC ANTAGONIST TROPICAMIDE
A. J. Betz et al.
NEUROSCIENCE (2009)
Tremorolytic effects of adenosine A2A antagonists:: implications for parkinsonism
John D. Salamone et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat
Anna R. Carta et al.
SYNAPSE (2008)
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease
Annalisa Pinna et al.
SYNAPSE (2007)
Characterization of the antiparkinsoni an effects of the new adenosine A2A receptor antagonist ST1535:: Acute and subchronic studies in rats
Elisabetta Tronci et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Potent, selective, and orally active adenosine A2A receptor antagonists:: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
Bernard R. Neustadt et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose Of L-dopa in unilaterally 6-OHDA-lesioned rats
Sarah Rose et al.
BRAIN RESEARCH (2007)
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Mats I. Ekstrand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The 6-hydroxydopamine model of Parkinson's disease
Nicola Simola et al.
NEUROTOXICITY RESEARCH (2007)
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice
Danqing Xiao et al.
JOURNAL OF NEUROSCIENCE (2006)
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease
Nicola Simola et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
ST 1535:: A preferential A2A adenosine receptor antagonist
Maria Antonietta Stasi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment
Annalisa Pinna et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats
J Bové et al.
SYNAPSE (2006)
Behavioral models of Parkinson's disease in rodents: A new look at an old problem
Gloria E. Meredith et al.
MOVEMENT DISORDERS (2006)
New adenosine A2A receptor antagonists:: Actions on Parkinson's disease models
A Pinna et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats
C Marin et al.
EXPERIMENTAL NEUROLOGY (2005)
Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats
K Ishiwari et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2005)
The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism
M Correa et al.
BEHAVIOURAL BRAIN RESEARCH (2004)
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions
N Simola et al.
EXPERIMENTAL NEUROLOGY (2004)
The scientific basis for the current treatment of Parkinson's disease
CW Olanow
ANNUAL REVIEW OF MEDICINE (2004)
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease
F Bibbiani et al.
EXPERIMENTAL NEUROLOGY (2003)
Adenosine A2A receptor antagonist treatment of Parkinson's disease
W Bara-Jimenez et al.
NEUROLOGY (2003)
Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD
RA Hauser et al.
NEUROLOGY (2003)
Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats
J Villanueva-Toledo et al.
NEUROSCIENCE LETTERS (2003)
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia
M Lundblad et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats
J Bové et al.
SYNAPSE (2002)
Modification of adenosine extracellular levels and adenosine A2A receptor mRNA by dopamine denervation
A Pinna et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
M Lundblad et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease
JD Oh et al.
AMINO ACIDS (2002)
SCH 58261, an A2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats
J Wardas et al.
SYNAPSE (2001)
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease
M Morelli et al.
NEUROLOGICAL SCIENCES (2001)
Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats
K Koga et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Lack of tolerance to motor stimulant effects of a selective adenosine A2A receptor antagonist
L Halldner et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
GS Gronseth et al.
NEUROLOGY (2000)
CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury
T Schallert et al.
NEUROPHARMACOLOGY (2000)
Share Paper
